Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
OBJECTIVE
Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years.


METHODS
1,500 patients with MS were assessed by a computerized cognitive battery measuring verbal and non-verbal memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills. Cognitive impairment was defined as below one standard deviation (SD) and severe cognitive impairment as below 2SD for age and education matched healthy population norms.


RESULTS
Cognitive performance in our cohort was poorer than healthy population norms. The most frequently impaired domains were information processing speed and executive function. MS patients with secondary-progressive disease course performed poorly compared with clinically isolated syndrome, relapsing-remitting and primary progressive MS patients. By the fifth year from disease onset, 20.9% of patients performed below the 1SD cutoff for impairment, p=0.005, and 6.0% performed below the 2SD cutoff for severe cognitive impairment, p=0.002. By 10 years from onset 29.3% and 9.0% of patients performed below the 1SD and 2SD cutoffs, respectively, p=0.0001. Regression modeling suggested that cognitive impairment may precede MS onset by 1.2 years.


CONCLUSIONS
The rates of cognitive impairment in this large sample of MS patients were lower than previously reported and severe cognitive impairment was evident only in a relatively small group of patients. Cognitive impairment differed significantly from expected normal distribution only at five years from onset, suggesting the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.
Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. Anat.Achiron@sheba.health.gov.il
Anat
A
Achiron
Joab
J
Chapman
David
D
Magalashvili
Mark
M
Dolev
Mor
M
Lavie
Eran
E
Bercovich
Michael
M
Polliack
Glen M
GM
Doniger
Yael
Y
Stern
Olga
O
Khilkevich
Shay
S
Menascu
Gil
G
Hararai
Micharel
M
Gurevich
Yoram
Y
Barak
D000328:Adult; D016000:Cluster Analysis; D003071:Cognition; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000503:physiopathology*; D013997:Time Factors